Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial [version 2; peer review: 2 approved].

Paul Gravestock,Emma Clark,Miranda Morton,Shirya Sharma,Holly Fisher,Jenn Walker,Ruth Wood,Helen Hancock,Nichola Waugh,Aislinn Cooper,Rebecca Maier,John Marshall,Robert Chandler,Amit Bahl,Simon Crabb,Suneil Jain,Ian Pedley, Rob Jones,John Staffurth,Rakesh Heer

NIHR open research（2023）

引用 0|浏览7

暂无评分

摘要

Whilst the trial did not complete to target, we have ascertained that men with advanced cancer are willing to take part in trials utilising biomarker guided treatment. A number of issues were identified that serve as important learning points in future clinical trials.

查看译文

关键词

biomarkers,castration-resistant,feasibility studies,male,prostatic neoplasms

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要